150 related articles for article (PubMed ID: 36280841)
1. Loss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases.
Wu HL; Yang ZR; Su YD; Ma R; Du XM; Gao Y; Li Y
World J Surg Oncol; 2022 Oct; 20(1):350. PubMed ID: 36280841
[TBL] [Abstract][Full Text] [Related]
2. The clinicopathological significance of TOP2A expression in malignant peritoneal mesothelioma.
Du X; Li X; Zhang B; Hao Z; Gao Y; Jiang X; Yang Z; Chen Y
Ann Diagn Pathol; 2023 Aug; 65():152155. PubMed ID: 37172528
[TBL] [Abstract][Full Text] [Related]
3. NPM2 in malignant peritoneal mesothelioma: from basic tumor biology to clinical medicine.
Wu HL; Yang ZR; Yan LJ; Su YD; Ma R; Li Y
World J Surg Oncol; 2022 Apr; 20(1):141. PubMed ID: 35490253
[TBL] [Abstract][Full Text] [Related]
4. Risk factors and prognosis of malignant peritoneal mesothelioma with paraneoplastic syndrome.
Liang XL; Su YD; Li XB; Fu YB; Ma R; Yang R; Wu HL; Li Y
World J Surg Oncol; 2024 Jan; 22(1):29. PubMed ID: 38267958
[TBL] [Abstract][Full Text] [Related]
5. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.
Zauderer MG; Martin A; Egger J; Rizvi H; Offin M; Rimner A; Adusumilli PS; Rusch VW; Kris MG; Sauter JL; Ladanyi M; Shen R
Lancet Digit Health; 2021 Sep; 3(9):e565-e576. PubMed ID: 34332931
[TBL] [Abstract][Full Text] [Related]
6. [Expression of CD24 gene in human malignant pleural mesothelioma and its relationship with prognosis].
Li B; Zhou CX; Pu YQ; Qiu L; Mei W; Xiong W
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Mar; 41(3):168-176. PubMed ID: 37006141
[No Abstract] [Full Text] [Related]
7. Clinical-pathological characteristics and prognostic factors for malignant peritoneal mesothelioma in the elderly.
Pan D; Wang M; Liu W; Li Y; Sang L; Chang B
BMC Gastroenterol; 2022 Jun; 22(1):292. PubMed ID: 35681152
[TBL] [Abstract][Full Text] [Related]
8. MUC1 has prognostic significance in malignant peritoneal mesothelioma.
Pillai K; Pourgholami MH; Chua TC; Morris DL
Int J Biol Markers; 2013 Sep; 28(3):303-12. PubMed ID: 23828409
[TBL] [Abstract][Full Text] [Related]
9. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
10. Key factors for successful cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat diffuse malignant peritoneal mesothelioma: results from specialized peritoneal cancer center in China.
Su YD; Yang ZR; Li XB; Yu Y; Du XM; Li Y
Int J Hyperthermia; 2022; 39(1):706-712. PubMed ID: 35485308
[TBL] [Abstract][Full Text] [Related]
11. Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.
Beije N; Kraan J; den Bakker MA; Maat APWM; van der Leest C; Cornelissen R; Van NM; Martens JWM; Aerts JGJV; Sleijfer S
Cell Oncol (Dordr); 2017 Oct; 40(5):511-519. PubMed ID: 28577209
[TBL] [Abstract][Full Text] [Related]
12. [Expression and clinical significance of COL1A1 and COL1A2 genes in malignant pleural mesothelioma tissues].
Li B; Pu YQ; Li ZL; Zhao Y; Zi JJ; Xiong W
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2022 Jul; 40(7):487-494. PubMed ID: 35915937
[No Abstract] [Full Text] [Related]
13. Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma.
Raphael J; Massard C; Gong IY; Farace F; Margery J; Billiot F; Hollebecque A; Besse B; Soria JC; Planchard D
Cancer Biomark; 2015; 15(2):151-6. PubMed ID: 25519011
[TBL] [Abstract][Full Text] [Related]
14. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
[TBL] [Abstract][Full Text] [Related]
15. Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status.
Rrapaj E; Giacometti L; Spina P; Salvo M; Baselli GA; Veggiani C; Rena O; Trisolini E; Boldorini RL
Pathology; 2021 Jun; 53(4):462-469. PubMed ID: 33272690
[TBL] [Abstract][Full Text] [Related]
16. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
Ortolan E; Giacomino A; Martinetto F; Morone S; Lo Buono N; Ferrero E; Scagliotti G; Novello S; Orecchia S; Ruffini E; Rapa I; Righi L; Volante M; Funaro A
Oncotarget; 2014 Aug; 5(15):6191-205. PubMed ID: 25026285
[TBL] [Abstract][Full Text] [Related]
17. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
Muraoka T; Soh J; Toyooka S; Aoe K; Fujimoto N; Hashida S; Maki Y; Tanaka N; Shien K; Furukawa M; Yamamoto H; Asano H; Tsukuda K; Kishimoto T; Otsuki T; Miyoshi S
Lung Cancer; 2013 Dec; 82(3):485-90. PubMed ID: 24168922
[TBL] [Abstract][Full Text] [Related]
18. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
Xu LL; Yang Y; Wang Z; Wang XJ; Tong ZH; Shi HZ
BMC Pulm Med; 2018 Apr; 18(1):56. PubMed ID: 29615010
[TBL] [Abstract][Full Text] [Related]
19. c-Met expression and MET amplification in malignant pleural mesothelioma.
Bois MC; Mansfield AS; Sukov WR; Jenkins SM; Moser JC; Sattler CA; Smith CY; Molina JR; Peikert T; Roden AC
Ann Diagn Pathol; 2016 Aug; 23():1-7. PubMed ID: 27402216
[TBL] [Abstract][Full Text] [Related]
20. Circulating endothelial cell (CEC) as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM).
Yoneda K; Tanaka F; Kondo N; Orui H; Hashimoto M; Takuwa T; Matsumoto S; Okumura Y; Tsubota N; Sato A; Tsujimura T; Kuribayashi K; Fukuoka K; Nakano T; Hasegawa S
Ann Surg Oncol; 2012 Dec; 19(13):4229-37. PubMed ID: 22825770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]